Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Conditions Studied
Interventions
- DRUG IPN01194
Study Locations (12)
Other
- Centre Léon Bérard - Lyon — Lyon
- Paris Saint-Louis — Paris
- Institut de Cancerologie de l'Ouest (St-Herblain) — Saint-Herblain
- IGR-Villejuif — Villejuif
- Barcelona - Val D'Hebron — Barcelona
- Fundacion Jimenez Diaz - Madrid — Madrid
- M.D. Anderson Cancer Center Madrid — Madrid
California
- The Angeles Clinic and Research Institute - California — Los Angeles
- UC San Diego Health System - La Jolla — San Diego
Connecticut
- Yale Cancer Center - New Heaven — New Haven
Tennessee
- Sarah Cannon Research Institute (SCRI) - Nashville — Nashville
Virginia
- Virginia Cancer Specialist — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2028-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305247
The ClinicalTrials.gov registry entry for NCT06305247 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 205 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention — of which IPN01194 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06305247 reports 12 study locations spanning 5 distinct geographic areas — top geographies include Other, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06305247 about?
NCT06305247 is a clinical study titled "A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours". The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places,...
What is the current status of trial NCT06305247?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-04-03. Estimated completion is 2028-03-20.
What conditions does trial NCT06305247 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06305247?
The interventions under investigation include: IPN01194 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06305247?
This trial is sponsored by Ipsen, which has 205 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06305247 being conducted?
This trial has 12 study locations across California, Connecticut, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.